The global continuous renal replacement therapy market size was valued at USD 1,356.7 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030.
Rising incidence of acute kidney injury (AKI), increasing incidence of sepsis, rapid increase in the volume of hospitals and urgent care centers, growing hospital admissions rate, and constant product launches by prominent market players are a few factors driving the demand for CRRT, thereby propelling the market growth. According to the American Kidney Fund, 37 million U.S. citizens are living with kidney disease and 807,000 people in the U.S. are diagnosed with kidney failure.
In the pre-COVID-19 era, the burden of COVID-19-associated AKI climbed to almost 4 million cases per year. CRRT was utilized to treat roughly 23,105 AKI patients per year prior to COVID-19. The need for CRRT appeared to be 5 times higher in COVID-19 patients, i.e., 4.9 percent, than in historical populations (0.9 percent). In community cohort datasets, 5%–15% of people hospitalized with COVID-19 needed dialysis. Moreover, in some North America regions, the number of people utilizing CRRT jumped by 370 percent over normal levels due to which the demand for the product increased during the pandemic. For instance, Fresenius Medical Care North America's Renal Therapies Group (FMCNA) released the first batch of multiBic dialysate solutions to U.S. hospitals in May 2020, according to an FDA emergency use authorization. These medicines were intended to provide CRRT to COVID-19-related individuals with acute renal failure.
Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market
Continuous Renal Replacement Therapy Market Report Highlights
• By product, the consumables segment held the largest revenue share of 60.6% in 2022. Although these products are low-priced, it is used repeatedly purchased; hence the market for consumables is the largest as compared to other segments
• Based on the modality, the Continuous Veno-venous Hemofiltration (CVVH) segment held the largest revenue share of 31.6% in 2022. Fluid overload situations, which are common in acute kidney injury patients in critical care units, are expected to increase, boosting the CVVH market's growth
• Asia Pacific was the fastest growing market for continuous renal replacement therapy with a growth rate of 9.8%. Various factors are responsible for the region growth such as technological advancement, growing healthcare infrastructure development as well as and presence of such a huge patient base in this region
Browse through Grand View Research's Medical Devices Industry Research Reports.
• The global sentinel node biopsy market size was estimated at USD 717.8 million in 2023 and is projected to grow at a CAGR of 7.0% from 2024 to 2030.
• The global market for endoscopy operative devices reached a value of USD 10.34 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030.
Continuous Renal Replacement Therapy Market Segmentation
Grand View Research has segmented the global continuous renal replacement therapy market on the basis of product, modality, and region:
Continuous Renal Replacement Therapy Product Outlook (Revenue, USD Million, 2018 - 2030)
• System
• Consumables
Continuous Renal Replacement Therapy Modality Outlook (Revenue, USD Million, 2018 - 2030)
• Slow Continuous Ultra-Filtration (SCUF)
• Continuous Venovenous Hemofiltration (CVVH)
• Continuous Venovenous Hemodialysis (CVVHD)
• Continuous Venovenous Hemodiafiltration (CVVHDF)
Continuous Renal Replacement Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Sweden
o Norway
o Denmark
• Asia Pacific
o China
o Japan
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa
o Saudi Arabia
o South Africa
o UAE
o Kuwait
Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.